[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Antonescu CR: Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol; 2008 May;21 Suppl 2:S31-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas.
  • Once a poorly understood pathologic entity, gastrointestinal stromal tumor (GIST) has emerged in recent years as a distinct oncologic-molecular paradigm that is now a leading model for kinase-targeted therapies in oncology.
  • A small subset of GIST show activating mutations in PDGFRA, encoding a related member of the type III receptor tyrosine kinase family.
  • The similarities in KIT immunoreactivity and ultrastructural appearance between GISTs and the intestinal pacemaker, the interstitial cells of Cajal (ICC), suggested that GISTs derive from or differentiate toward the ICC lineage.
  • This review will include a summary of the biology behind the specific targeted therapies, emphasizing the central role of KIT and PDGFRA oncogenic mutations in GISTs and their clinical and pathologic correlates.
  • The morphologic and molecular changes that appear with imatinib treatment, such as response and acquired imatinib resistance, are being discussed.
  • The success GIST story based on targeted molecular paradigm may be applied in other imatinib-responsive sarcoma, such as dermatofibrosarcoma protuberans.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems / trends. Gastrointestinal Stromal Tumors / drug therapy. Pathology, Clinical / trends. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437171.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 40
  •  go-up   go-down


2. Kitagawa Y, Sameshima Y, Shiozaki H, Ogawa S, Masuda A, Mori S, Teramura M, Masuda M, Kameoka S, Motoji T: Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation. Int J Hematol; 2008 May;87(4):410-3
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation.
  • Isolated primary granulocytic sarcoma is a rare disease that presents as an extramedullary tumor of myeloid lineage cells.
  • Herein, we report the case of a 33-year-old woman with a primary isolated granulocytic sarcoma which originated in the small intestine.
  • After she recovered from surgery, she received intensive chemotherapy equivalent to that for AML, followed by allogeneic bone marrow transplantation from an HLA-matched, unrelated donor.
  • This case illustrates the effectiveness of our therapeutic strategy for isolated granulocytic sarcoma, not only with surgical resection of the tumor and intensive chemotherapy equivalent to that for AML, but also with allogeneic bone marrow transplantation, performed while no sign of AML is observed.
  • [MeSH-major] Bone Marrow Transplantation. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology. Sarcoma, Myeloid / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365139.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Xavier SG, Fagundes EM, Hassan R, Bacchi C, Conchon M, Tabak DG, Spector N, Zalcberg IR: Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature. Leuk Res; 2003 Nov;27(11):1063-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature.
  • The possibility of an association between the development of granulocytic sarcoma of the small intestine (GSSI) and the M4Eo subtype of AML was suggested in nine previous case reports.
  • Here we report an aleukaemic case of GSSI with inv(16) and its molecular equivalent, the CBFbeta/MYH11 fusion gene, detected by reverse transcriptase-polymerase chain reaction (RT-PCR), that after treatment with conventional AML chemotherapy followed by autologous bone marrow transplantation, achieved complete haematological and molecular remission on bone marrow examination.
  • After chemotherapy, a thickened ileum wall positive for CBFbeta/MYH11 on tumour mass samples was still observed on computed tomography (CT) studies, raising the question of residual GS representing a reservoir of malignant cells.
  • This case demonstrates the critical need of multidisciplinary diagnosis and follow-up of this entity combining immunopathologic, cytogenetic and molecular studies, reinforcing the potentiality of risk-adapted therapy strategies, as it is increasingly claimed for patients with overt AML.
  • [MeSH-major] Intestinal Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Sarcoma, Myeloid / genetics
  • [MeSH-minor] Adult. Humans. Ileum / radiography. Leukemia / complications. Male. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12859999.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 24
  •  go-up   go-down


Advertisement
4. Beyrouti ML, Abid M, Beyrouti R, Ben Amar M, Gargouri F, Frikha F, Affes N, Boujelbene S, Ghorbel A: [Sarcomas of the small intestine]. Presse Med; 2005 Mar 12;34(5):385-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcomas of the small intestine].
  • Sarcomas of the small intestine are rare, clearly differentiated, malignant, mesenchymatous tumours that can be of smooth muscle, Schwann cell or fibroblastic origin.
  • From a clinical point of view, the pain and abdominal mass are the 2 types of symptoms that frequently reveal the disease.
  • In rare cases, sarcomas of the small intestine are manifested by an acute complication.
  • No imaging method can clearly confirm the diagnosis.
  • Before immunohistochemistry, differential diagnosis was made on undifferentiated mesenchymatous "stromal" tumours, which are also rare.
  • The benefits provided by chemotherapy and radiotherapy are limited because of the low mitotic activity of the tumour cells and its weak vascularisation.
  • Long-term survival is limited by poor prognosis criteria: high grade malignancy, size greater than 5 cm, tumour extension, perforation of the tumour, quality of surgical resection and histological type.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859576.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 46
  •  go-up   go-down


5. Van Glabbeke M, Verweij J, Casali PG, Simes J, Le Cesne A, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY: Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer; 2006 Sep;42(14):2277-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
  • The aim of this study was to identify prognostic factors for toxicity to treatment with imatinib.
  • The risk of non-haematological toxicities was dose dependent and higher in females (oedema, nausea, diarrhoea), and in patients of advanced age (oedema, rash fatigue), poor performance status (fatigue and nausea), prior chemotherapy (fatigue), tumour of identified gastrointestinal origin (diarrhoea) and small lesions (rash).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastrointestinal Stromal Tumors / drug therapy. Piperazines / adverse effects. Pyrimidines / adverse effects

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876399.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-29; United States / NCI NIH HHS / CA / 5U10 CA11488-34
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


6. Svrcek M, Tiret E, Bennis M, Guyot P, Fléjou JF: KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case. Dis Colon Rectum; 2009 Jan;52(1):154-8
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case.
  • Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), has been identified in all four forms of Kaposi's sarcoma (classic, endemic, HIV-associated and iatrogenic).
  • We report the rare case of an intestinal (small intestine and rectosigmoid) Kaposi's sarcoma in a 62-year-old HIV-negative man with ulcerative colitis.
  • This patient was receiving immunosuppressive therapy with steroids and azathioprine.
  • To date, the causative role of KSHV/HHV8 in the pathophysiology of Kaposi's sarcoma associated with ulcerative colitis has only been proven for cutaneous lesions but not for intestinal lesions of Kaposi's sarcoma.
  • We report for the first time, the expression of HHV8 (by using immunohistochemistry) in colonic Kaposi's sarcoma in a patient with an ulcerative colitis-related tumor.
  • At laparotomy, numerous Kaposi's sarcoma lesions were found in the small intestine, which were left in situ.
  • Forty months after surgery and following withdrawal of immunosuppressive therapy, the patient had no evidence of any disease and a normal abdominal and thoracic CT scan.
  • Cases of colorectal Kaposi's sarcoma complicating inflammatory bowel disease should be managed with a conservative approach and discontinuation of the immunosuppressive treatment.
  • However, discontinuation of the immunosuppression is not always possible and in those cases chemotherapy may be indicated.
  • [MeSH-major] Colitis, Ulcerative / drug therapy. Colorectal Neoplasms / complications. Herpesvirus 8, Human. Immunosuppressive Agents / therapeutic use. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / virology

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273971.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


7. Lee SY, Park SJ, Kim YH, Lee JH: Nonleukemic granulocytic sarcoma presenting as intussusception of small bowel. Int J Clin Oncol; 2008 Oct;13(5):467-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonleukemic granulocytic sarcoma presenting as intussusception of small bowel.
  • Granulocytic sarcoma (GS) is defined as a localized tumor mass composed of myeloid blasts and/or immature myeloid cells in an extramedullary site.
  • In rare cases, it occurs as a "preleukemic" condition and may precede the onset of AML, which occurs within several months if the patient is not treated with AML-type systemic chemotherapy.
  • Recently, we discovered one case of nonleukemic GS in the small intestine incidentally when intussusception was suspected.
  • The patient visited the emergency department, in October 2006, with symptoms of small-bowel obstruction.
  • Intussusception due to a small-intestinal mass was suspected after evaluation, and small-intestine segmental resection was performed.
  • The patient received three cycles of chemotherapy, applied as for AML (cytosine arabinoside and anthracycline), and is currently, as of October 29, 2007, showing no other marked indisposition; he has been disease-free for 12 months.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small. Intussusception / diagnosis. Sarcoma, Myeloid / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1570-4 [17090205.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):912-7 [2423654.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1800-16 [7602369.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):745-8 [16891824.001]
  • (PMID = 18946761.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Rénard C, Girard S, Pracros JP, Dijoud F, André JM, Mialou V, Bertrand Y: [Granulocytic sarcoma, a diagnostic challenge: 3 pediatric cases]. Arch Pediatr; 2010 Feb;17(2):149-53
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocytic sarcoma, a diagnostic challenge: 3 pediatric cases].
  • Granulocytic sarcoma (GS) is a rare extramedullary tumor frequently associated with acute myeloblastic leukemia (AML).
  • We report 3 cases of pediatric granulocytic sarcomas with various locations: skin, orbit, and bowel.
  • In all 3 cases, the diagnosis was delayed or initially missed.
  • GS is treated with chemotherapy, like AML.
  • [MeSH-major] Facial Neoplasms / diagnosis. Intestinal Neoplasms / diagnosis. Intestine, Small. Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary / diagnosis. Orbital Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biopsy. Bone Marrow / pathology. Bone Marrow Transplantation. Child, Preschool. Combined Modality Therapy. Diagnostic Errors. Female. Follow-Up Studies. Humans. Infant. Leukemia, Biphenotypic, Acute / diagnosis. Leukemia, Biphenotypic, Acute / drug therapy. Leukemia, Biphenotypic, Acute / pathology. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19945260.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Wheeler DW, Baigrie RJ: Palliative surgery for acute bowel obstruction caused by Kaposi's sarcoma in a patient with AIDS. Int J Clin Pract; 2003 May;57(4):347-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative surgery for acute bowel obstruction caused by Kaposi's sarcoma in a patient with AIDS.
  • We report a 39-year-old man who developed intermittent nausea and vomiting, which was originally thought to be a side-effect of the chemotherapy he was receiving for facial Kaposi's sarcoma.
  • However, he was found to have intraperitoneal Kaposi's sarcoma causing small bowel obstruction, which was successfully excised at laparotomy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Ileal Neoplasms / complications. Intestinal Obstruction / etiology. Sarcoma, Kaposi / complications


10. Kimura Y, Sawai N, Okuda H: Antitumour activity and adverse reactions of combined treatment with chitosan and doxorubicin in tumour-bearing mice. J Pharm Pharmacol; 2001 Oct;53(10):1373-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumour activity and adverse reactions of combined treatment with chitosan and doxorubicin in tumour-bearing mice.
  • We examined the antitumour activity and adverse reactions, such as myelotoxicity, gastrointestinal toxicity and body-weight loss,of the cancer chemotherapy drug doxorubicin when given with chitosan in sarcoma 180-bearing mice.
  • The orally administered chitosan (400 and 800 mg kg(-1) twice daily) prevented doxorubicin-induced body-weight loss and small-intestinal mucosal injury.
  • It seems likely that the mechanisms by which the orally administered chitosan protects against doxorubicin-induced gastrointestinal toxicity may be due to the formation of doxorubicin-chitosan complex in the small-intestinal mucosa through the diffusion of chitosan into the small-intestinal villi.
  • In conclusion, our data suggest that the oral administration of chitosan prevents the gastrointestinal mucositis associated with doxorubicin therapy.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Chitin / therapeutic use. Doxorubicin / therapeutic use. Sarcoma 180 / drug therapy
  • [MeSH-minor] Animals. Body Weight / drug effects. Chitosan. Injections, Intraperitoneal. Intestinal Mucosa / enzymology. Male. Mice. Mice, Inbred ICR. Organ Size. Sucrase / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHITIN UNSPECIFIED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697545.001).
  • [ISSN] 0022-3573
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 1398-61-4 / Chitin; 80168379AG / Doxorubicin; 9012-76-4 / Chitosan; EC 3.2.1.48 / Sucrase
  •  go-up   go-down


11. Anyanwu SN, Nwofor AM: Primary jejuno-ileal neoplasms in eastern Nigeria. Niger Postgrad Med J; 2003 Mar;10(1):23-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small intestinal neoplasms are uncommon with reported incidences of less than 1% of GI neoplasms.
  • A retrospective review of cases of small intestinal neoplasms seen by the authors in a ten-year period is presented.
  • Six patients presented with intestinal obstruction, 3 with features of chronic ill-health while 1 was an incidental finding.
  • The rest consisted of lymphosarcoma [5],adenocarcinoma [3] while 1 patient had leiomyo-sarcoma.
  • Treatment offered included resection of small gut in 7 patients and ileo-colectomy in 3 patients.
  • Three patients with lymphosarcoma had a full course of cytotoxic chemotherapy.
  • Neoplasms of the small gut presents late in our environment.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Intestinal Neoplasms / etiology. Male. Middle Aged. Nigeria

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12717460.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Nigeria
  •  go-up   go-down


12. Atmatzidis KS, Pavlidis TE, Galanis IN, Papaziogas BT, Papaziogas TB: Malignant fibrous histiocytoma of the abdominal cavity: report of a case. Surg Today; 2003;33(10):794-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma originating from fibroblast cells, characterized by a high rate of metastasis or recurrence.
  • A computed tomography (CT) scan of the abdomen revealed multiple solid tumors in the peritoneal cavity.
  • We performed exploratory laparotomy and found at least 15 solid whitish tumors attached to the wall of the small intestine, as well as to the parietal peritoneum.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of the resected specimens established the definite diagnosis of a pleomorphic MFH.
  • The patient had an uneventful postoperative course and was given adjuvant chemotherapy.
  • We review the clinical picture of this tumor in the abdominal cavity, and discuss its diagnosis, pathogenesis, and treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Intestinal Neoplasms / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Intestine, Small. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14513333.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Talamonti MS, Goetz LH, Rao S, Joehl RJ: Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg; 2002 May;137(5):564-70; discussion 570-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management.
  • HYPOTHESIS: This study was done to review the clinical presentation, surgical management, pathologic features, and prognostic factors for primary small-bowel cancers.
  • The distribution of tumors by histological features was as follows: adenocarcinoma (33%), carcinoid tumor (29%), lymphoma (19%), and sarcoma (19%).
  • Cumulative 5-year survival rate was 37% in the adenocarcinoma group, 64% in the carcinoid tumor group, 29% in the lymphoma group, and 22% in the sarcoma group.
  • Patient age, tumor location, histological grade, and use of chemotherapy and radiation therapy did not significantly influence survival.
  • The median time to recurrence was 16 months.
  • Twenty-one patients (16%) developed associated primary cancers.
  • [MeSH-major] Intestinal Neoplasms / mortality. Intestinal Neoplasms / surgery
  • [MeSH-minor] Actuarial Analysis. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Carcinoid Tumor / mortality. Carcinoid Tumor / surgery. Female. Humans. Intestine, Small. Lymphoma / mortality. Lymphoma / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Sarcoma / mortality. Sarcoma / surgery. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11982470.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Ryan P, Nguyen VH, Gholoum S, Carpineta L, Abish S, Ahmed NN, Laberge JM, Riddell RH: Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract. Am J Surg Pathol; 2009 Mar;33(3):475-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy.
  • We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma.
  • Immunohistochemistry can rule out many of these morphologically similar tumors but differentiation from clear cell sarcoma may require reverse transcription-polymerase chain reaction.
  • We discuss the determination of pathologic features indicative of malignancy in PEComa, which is complicated in the gastrointestinal tract due to the small number of cases, variability of pathologic features reported, and inconsistent reporting of outcome.
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Digestive System Surgical Procedures. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092636.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Dusenbery KE, Potish RA, Argenta PA, Judson PL: On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol; 2005 Jun;28(3):295-300
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This retrospective report analyzes patterns of failure, survival, and toxicity in 42 women with stage I and 7 patients with stage II uterine sarcomas treated from 1972 through 1998 to identify patients likely to benefit from pelvic or abdominal radiotherapy and chemotherapy.
  • Four of these patients also received adjuvant chemotherapy.
  • Acute toxicity was acceptable as measured by a median 1-kg weight loss from radiotherapy and a 2% rate of failure to complete therapy.
  • Chronic toxicity consisted of 3 small bowel obstructions and 1 sigmoid colon obstruction.
  • Although the frequent occurrence of peritoneal failures suggests a role for prophylactic abdominal radiation for mixed mullerian tumors, more effective systemic therapy is necessary to substantially increase the chance of cure for women with early-stage uterine sarcomas.
  • [MeSH-major] Sarcoma / radiotherapy. Uterine Neoplasms / radiotherapy
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / prevention & control. Abdominal Neoplasms / secondary. Antineoplastic Agents / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Dactinomycin / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Humans. Hysterectomy / methods. Ifosfamide / therapeutic use. Intestinal Obstruction / etiology. Leiomyosarcoma / mortality. Leiomyosarcoma / radiotherapy. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Life Tables. Mixed Tumor, Mullerian / mortality. Mixed Tumor, Mullerian / radiotherapy. Mixed Tumor, Mullerian / secondary. Mixed Tumor, Mullerian / surgery. Neoplasm Staging. Pelvic Neoplasms / mortality. Pelvic Neoplasms / prevention & control. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. Radiation Injuries / etiology. Radiotherapy, Adjuvant / adverse effects. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Failure

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923804.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 1CC1JFE158 / Dactinomycin; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 18
  •  go-up   go-down


16. Delacruz V, Takahashi H, Nishida S, Tzakis A, Ruiz P: Segmental xanthomatosis of the small intestine. A case report and review of the literature. Hum Pathol; 2009 Jan;40(1):139-42
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmental xanthomatosis of the small intestine. A case report and review of the literature.
  • Intestinal xanthomatosis is a rare, nonneoplastic lesion that may involve the small bowel in a localized or generalized way.
  • It may be a cause of clinically significant obstruction and should be included in the differential diagnosis with other causes of bowel obstruction, particularly in patients with history of radiation therapy or chemotherapy.
  • The patient was a 22-year-old man who developed intestinal obstruction 16 years after radiation therapy for Ewing sarcoma of the right hip.
  • [MeSH-major] Ileum / pathology. Intestinal Obstruction / etiology. Intestinal Obstruction / pathology. Intestine, Small / pathology. Xanthomatosis / complications
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Radiotherapy / adverse effects. Sarcoma, Ewing / radiotherapy. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2009 Jul;40(7):1052; author reply 1052 [19342078.001]
  • (PMID = 18755495.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


17. Tanigawa M, Kimura M, Ichioka M, Saito K, Kimura M: [A case of true pulmonary carcinosarcoma]. Nihon Kokyuki Gakkai Zasshi; 2003 Jul;41(7):496-501
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was therefore true pulmonary carcinosarcoma.
  • The sarcoma component recurred in the remaining part of the left lung.
  • However, distant metastases occurred to the brain, liver, and small intestine, and digestive tract bleeding also occurred.
  • Nevertheless, chemotherapy, linac radiosurgery, percutaneous radiofrequency ablation, and partial small intestinal resection combined with rectal resection were performed.
  • Liver metastatic lesions were determined to be the adenocarcinomatous component, and the other recurrent or metastatic lesions, except for those in the brain, were all composed of poorly-differentiated sarcomatous tissue.
  • [MeSH-minor] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Chondrosarcoma / pathology. Humans. Intestinal Neoplasms / secondary. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931680.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Lee KH, Fiedler P, Passarelli J, Bobrow S: Autoimmune hemolytic anemia associated with postirradiation malignant stromal tumor (leiomyosarcoma) of the jejunum. Ann Diagn Pathol; 2000 Dec;4(6):367-9
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a patient who presented with autoimmune hemolytic anemia and small bowel obstruction secondary to a malignant stromal tumor (leiomyosarcoma) of the jejunum, 25 years postchemotherapy and radiation treatment for stage IIA Hodgkin's disease.
  • The patient was treated with corticosteroid therapy and surgical resection of the jejunal tumor.
  • We conclude that autoimmune hemolytic anemia may be an unusual presentation for postirradiation sarcoma.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Intestinal Obstruction / etiology. Intestine, Small / pathology. Jejunal Neoplasms / etiology. Leiomyosarcoma / etiology. Neoplasms, Radiation-Induced / etiology
  • [MeSH-minor] Chemotherapy, Adjuvant. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Male. Middle Aged. Prednisone / therapeutic use. Radiotherapy / adverse effects


19. Boehm R, Till H, Landes J, Schmid I, Joppich I: Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report. Eur J Pediatr Surg; 2003 Aug;13(4):272-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report.
  • In older patients and adolescents, the diagnosis can be complicated due to the lower incidence and variable subacute symptoms.
  • External diagnostics showed no pathological signs or were misinterpreted as a malfunction of intestinal motility.
  • An ileoilealic intussusception was found, caused by a small bowel tumour, which almost completely obstructed the intestinal lumen.
  • It was resected and bowel continuity was re-established.
  • Histopathology revealed a very rare, highly malignant mesenchymal Ewing sarcoma, infiltrating the complete bowel wall.
  • After the postoperative course, the patient was transferred to our oncological department for chemotherapy.
  • In older children or young adults, intestinal malignancies are extremely rare.
  • Nevertheless, if these patients suffer from unspecific complaints of chronic intestinal obstruction, a tumour must be ruled out.
  • A Ewing sarcoma may be responsible for an intussusception.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / therapy. Ileal Diseases. Ileal Neoplasms / therapy. Intussusception / surgery. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Cisplatin / administration & dosage. Combined Modality Therapy. Digestive System Surgical Procedures / methods. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Stem Cell Transplantation. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13680499.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


20. Kumar B, Bommana V, Irani F, Kasmani R, Mian A, Mahajan K: An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma. QJM; 2009 Jul;102(7):491-3
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma.
  • [MeSH-major] Intestinal Obstruction / etiology. Intestine, Small. Sarcoma, Myeloid / complications
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cytarabine / therapeutic use. Female. Humans. Idarubicin / therapeutic use. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / drug therapy. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433489.001).
  • [ISSN] 1460-2393
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down






Advertisement